ArticleFuture oncology (London, England)2025
Biomarker testing, treatment patterns and outcomes in previously treated pMMR or non-MSI-H metastatic colorectal cancer patients.
Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Biological and Targeted Therapies in the Multidisciplinary Management of Gastrointestinal Cancers.Cancers · 2026Review
- Time to Treatment Discontinuation and Cost Effectiveness of Third-Line Therapies in Advanced Colorectal Cancer: Real-World Evidence from the NIH All of Us Research Program.Drugs - real world outcomes · 2026Article
- National Patterns of Biomarker Testing in Colorectal, Lung, and Prostate Cancers: Insights From the NIHClinical Medicine Insights. Oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo assess biomarker testing utilization, treatment patterns, and clinical outcomes in previously treated proficient mismatch repair deficient (pMMR) or non-microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) patients. MATERIALS &
methodsUsing the iKnowMed electronic health record database, this study included pMMR/non-MSI-H adult mCRC patients previously treated with standard-of-care (SoC) chemotherapies between 1 January 2016 and 31 December 2021. Patients were censored for overall survival (OS) and real-world progression-free survival (rwPFS) at their last visit date or the end of study period, 31 August 2022.
resultsMSI/MMR testing was conducted in 70.9% of mCRC patients. In 292 previously treated mCRC patients, 69.5% received SACT (regorafenib:14.8%, trifluridine+tipiracil (TAS-102):12.3%, other SACT:72.9%), 28.8% received BSC and 1.7% received no BSC/SACT. The most common other SACT included irinotecan- (37.4%) and oxaliplatin-based (14.8%) therapies. The most patients were tested for KRAS (89%) and BRAF (81%). Overall, the median (95% CI) OS and rwPFS was 7.4(5.8,8.8) and 3.5(3.2,4.3) months, respectively.
conclusionsOnly 70.9% of mCRC patients received guideline-recommended MSI/MMR testing, indicating a need for improved testing rates. Additionally, only 27.1% of previously treated mCRC patients received SoC options (regorafenib/TAS-102). The real-world variability in treatment choices and a high rate of chemotherapy rechallenge in subsequent lines highlight an unmet need in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.